

**NEWS RELEASE**

## **iX Biopharma to Export Sublingual Medicinal Cannabis Wafer to New Zealand**

**Singapore, 27 July 2021** – Specialty pharmaceutical company **iX Biopharma Ltd** (SGX:42C) (“iX Biopharma” or, “the Company”) has, through its wholly-owned subsidiary iX Syrx Pty Ltd, entered into an agreement with medicinal cannabis company [Organic Genetics Group Limited](#) (“OGG”) to supply the Company’s novel sublingual medicinal cannabis wafers in New Zealand.

The supply agreement will allow iX Biopharma to access the country’s pharmaceutical market through OGG’s commercial partnership with its shareholder, ANZ Pharma. ANZ Pharma is a reseller of leading pharmaceutical, health and beauty care products with an extensive distribution network of 1,108 pharmacies comprising owned and independent pharmacies, including Green Cross Health, Chemist Warehouse, and Countdown Pharmacies across the North and South Islands of New Zealand. In addition to direct pharmacy access, OGG will leverage ANZ Pharma’s partnership with Tamaki Health Group, New Zealand’s largest independent primary healthcare group with more than 50 clinics and 400,000 enrolled patients, and additional links to over 400 primary care doctors.

The agreement comes close on the heels of the Company’s shipment of Xativa to Brazil, following the product’s inclusion in the Australian Register of Therapeutic Goods (ARTG) list of drugs approved for export. The ARTG listing paves the way for the Company to expand its customer base beyond Australia and grow into a global medicinal cannabis provider.

Under the terms of the agreement, OGG will be responsible for securing the requisite approvals from the Medicinal Cannabis Agency under the Ministry of Health in New Zealand, and other relevant authorities for the import of the medicinal cannabis wafer into the country. Supply of the wafers by iX Biopharma to OGG will commence after the approvals are in place.

The Company utilises its proprietary WaferiX drug delivery technology to produce innovative sublingual medicinal cannabis products. Its first medicinal cannabis product, Xativa, is the world’s first freeze-dried sublingual CBD (cannabidiol) wafer, and was launched in Australia in 2020 via the country’s Special Access Scheme and Authorised Prescriber Scheme. Incorporating a nano-emulsion of broad-spectrum cannabidiol (“CBD”), the drug is prescribed by doctors for a wide variety of

conditions, including chronic pain, anxiety, insomnia and certain inflammatory and motor diseases, to patients who have not been effectively treated with other drugs.

Compared to other cannabis products, the Company's sublingual medicinal cannabis products have the potential to provide patients with rapid absorption, faster therapeutic effect and a more predictable outcome. The drug is supplied in the form of a fixed dosage form that is convenient for doctors and patients.

**Contact for media:**

**Yee Chia Hsing**

Director of Corporate Affairs

T: +65 6235 2270

E: [chiahsing.yee@ixbiopharma.com](mailto:chiahsing.yee@ixbiopharma.com)

**Eva Tan**

Chief Commercial Officer

T: +65 6235 3212

E: [eva.tan@ixbiopharma.com](mailto:eva.tan@ixbiopharma.com)

**Alvina Tan**

Media & Investor Relations Consultant

T: +65 9787 7267

E: [alvina.tan@arkadvisors.com.sg](mailto:alvina.tan@arkadvisors.com.sg)

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst.*

*This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr Lance Tan, Senior Vice President at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.*